Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LN-145 tumor-infiltrating lymphocyte therapy in metastatic non-small-cell lung cancer
2024-510778-26-00Phase 2Authorised
- Sponsor
- Iovance Biotherapeutics
- Start
- Dec 2021
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 9
01
Overview
Phase 2, open-label trial of LN-145 in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoint: Objective response rate. Planned start Dec 2021; status: authorised.
02
Drugs
LN-145
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-510778-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510778-26-00.